Detecting residual host cell DNA with Droplet Digital PCR technology
Cell & Gene Therapy Insights 2022; 8(3), 443
10.18609/cgti.2022.065
Watch the video or read the poster to find out:
- How ddPCR technology may be leveraged for the effective removal of residual host cell DNA from cell and gene therapy products, thus enhancing product and patient safety
- What specific benefits and advantages ddPCR technology can offer compared to alternative tools for residual host cell DNA detection, sizing, and quantification
We hope you enjoyed this FastFacts video. You can also view the summary PDF here
Authorship & conflict of interest
Contributions: All named authors take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Acknowledgements: None
Disclosure and potential conflicts of interest: The author is a Bio-Rad Inc. employee and stock holder.
Funding declaration: The authors received no financial support for the research, authorship and/or publication of this article.
Article & copyright information
Copyright: Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.
Attribution: Copyright © 2022 Bio-Rad Inc. Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0.
Article source: From a FastFacts video recorded on: Apr 1 2022; Publication date: Apr 19 2022.